Slide 1: Investor Presentation
Investor Presentation March 2024
Slide 2: Disclaimer
Disclaimer This presentation includes express or implied statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statem
Slide 3: Our mission: To make care easier every day
Our mission To make care easier every day 3
Slide 4: Phreesia is Patient Intake
>3,900 Average Activated patients. is Patient Intake healthcare services Improved outcomes. clients (“AHSCs”)1,2 >$3.9B patient payments processed latest twelve months3,4 Who we are: Leading provider of comprehensive solutions that transform the healthcare experience by activating patients in their
Slide 5: Attractive industry tailwinds
Attractive industry tailwinds Staffing Increasing patient Accelerated Changing care Patient-centered challenges responsibility digitization models care • 1.3M healthcare • $610B out-of-pocket • Consumer demand • Providers incentivized • Need to directly staff represent $37B spend by 20302 for inform
Slide 6: Our value proposition and how we make money
Our value proposition and how we make money Healthcare Services Orgs Patients Life Sciences and Payer Organizations • Simplified operations and enhanced • Improved patient experience • Direct digital communications Value proposition staff efficiency • High patient usage • Improved brand conversion a
Slide 7: Used by all types of healthcare provider and life sciences organizations
Used by all types of healthcare provider and life sciences organizations Providers Life Sciences and Payer Organizations Phreesia serves more than 3,900 AHSCs1,2 Pharma Manufacturers and Health Plans Health systems Specialty practices More than 90 pharmaceutical brands3 Federally Qualified Hospitals
Slide 8: Innovative software to improve efficiency, cash flow and the patient experience
Innovative software to improve efficiency, cash flow and the patient experience Access to care Registration Revenue cycle Network Provider directory for Mobile and in-office Education and engagement before, Point-of-service payments patients seeking care intake modalities during and after the visit
Slide 9: Multiple growth opportunities
Multiple growth opportunities Cross-sell new Grow footprint within Increasing investments to Land new clients applications to existing Partnerships and M&A existing clients drive growth clients • Direct sales model • Additional providers • Proven ability to • New product and • Opportunistic approach
Slide 10: Our current addressable market
Our current addressable market Consumer-related transaction Subscription-based revenue Network solutions4 and payment processing fees ~50K addressable healthcare services clients1 DTC point-of-care in United States $95B addressable out-of-pocket 3 marketing spend 2 ~1.4M individual providers in Unit
Slide 11: Financial Overview
Financial Overview 11
Slide 12: Scalable and predictable sources of revenue
Scalable and predictable sources of revenue Revenue model Drivers FY24 % rev Subscription • New healthcare services clients and related services1 • Includes base package and add-on applications P • Majority of fees charged per provider per month (PPPM) • Expansion within existing clients 46% r • New
Slide 13: Nearly tripled quarterly revenue since Q1 fiscal 2021
Nearly tripled quarterly revenue since Q1 fiscal 2021 Quarterly Revenue1 (FY2021-FY20242) Subscription and Related Services Network Solutions Payment Processing Fees $95M $92M $86M $84M 2.8x $73M $77M $68M $46M $43M $63M $39M $38M $58M $56M $36M $33M $51M $48M $31M $29M $42M $24M $26M $38M $35M $23M
Slide 14: AHSCs (FY2021-FY2024)
AHSC AHSCs1 (FY2021-FY20242) 3,962 3,688 3,445 3,309 3,140 2,982 2,776 $11.5k 2,526 $10.4 k 2,311 2,097 1,987 $9.0 1,902 $9.4 1,737 1,808 k $9.3 k 1,632 1,668 $8.1 $8.2 k k k Q1’21 Q2’21 Q3’21 Q4’21 Q1’22 Q2’22 Q3’22 Q4’22 Q1’23 Q2’23 Q3’23 Q4’23 Q1’24 Q2’24 Q3’24 Q4’24 FY 2021 FY 2022 FY 2023 FY 20
Slide 15: Total revenue per AHSC (FY2021-FY2024)
Total revenue per AHSC2 (FY2021-FY2024) Subscription and Related Services Network Solutions Payment Processing Fees $26.7K $25.4K $25.7K $25.3K $25.1K $25.1K $24.9K $24.8K $24.4K $24.5K $24.4K $24.0K $23.1K $22.1K $21.0K $20.5K $11.6K $11.5K $11.5K $11.4K $11.4K $11.5K $11.1K $11.4K $11.5K $11.2K $1
Slide 16: Consistent payment volume and transaction-level economics
Consistent payment volume and transaction-level economics Patient Payment Volume (FY2021-FY20241) Take Rate Percentage2 $1,016 Patient Payment Volume (in millions)3 $989 $977 $965 Payment Facilitator Volume Percentage4 84% $837 82% 80% $811 $815 $821 79% 78% 78% 79% 79% 81% 81% 82% 82% 82% 82% $701
Slide 17: Fiscal fourth quarter 2024 results
Fiscal fourth quarter 2024 results Total Revenue ($M) AHSCs1 Total Revenue Per AHSC2 Adj. EBITDA3 ($M) $(411) Network Solutions 26% Healthcare Services 24% $24,390 $24,842 $95.0 3,962 $23,979 $91.6 3,688 $76.6 3,140 24% $65.8 $69.2 $55.6 $(3.5) $(6.6) 23% $(17.6) $21.0 $25.8 $25.8 Q4 Q3 Q4 Q4 Q3 Q4
Slide 18: Fiscal year 2024 results
Fiscal year 2024 results Total Revenue ($M) AHSCs1 Total Revenue Per AHSC2 Adj. EBITDA3 ($M) 26% Network Solutions 1% Healthcare Services 3,601 27% $356.3 $102,812 2,856 $98,358 $98,944 $280.9 $(35.4) 25% 2,074 $213.2 $260.0 $(59.0) $207.3 $160.7 31% $96.3 $73.6 $52.5 $(92.5) FY2022 FY2023 FY2024 FY
Slide 19: Fiscal year 2025 outlook
Fiscal year 2025 outlook FY2025 Outlook4 1 $424M to $434M Total Revenue +19%-22% y/y 2 $12M to $20M Adj. EBITDA3 1 Revenue outlook issued on December 5, 2023 and reaffirmed on March 14, 2024. 2 Adjusted EBITDA outlook issued on March 14, 2024. 3 We have not reconciled the Adjusted EBITDA outlook to
Slide 20: Financial Appendix
Financial Appendix 20
Slide 21: Detailed Income Statement
Detailed Income Statement1 $ and shares in Millions Fiscal year ended January 31 Fiscal quarter ended January 31 FY 2022 FY 2023 FY 2024 Q4 2023 Q4 2024 Revenue: Subscription and related services $ 95.5 $ 129.0 $ 165.4 $ 35.8 $ 45.7 Payment processing fees 65.2 78.4 94.6 19.8 23.5 Total healthcare s
Slide 22: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation1 $M Fiscal year ended Jan 31 2020 2021 2022 2023 2024 Net loss $ (20.3) $ (27.3) $ (118.2) $ (176.1) $ (136.9) Interest expense (income), net 2.4 1.6 1.1 (1.1) (2.2) (Benefit) provision for income taxes (1.8) — 0.2 0.5 1.5 Depreciation and amortization 13.9 15.9 21.3 2
Slide 23: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation1 $M Fiscal quarter ended January 31, October 31, January 31, 2023 2023 2024 Net loss $ (38.0) $ (31.9) $ (30.6) Interest income, net (1.6) (0.5) (0.2) (Benefit) provision for income taxes (0.2) 0.4 0.2 Depreciation and amortization 6.9 7.5 8.3 Stock-based compensation